Whanin Pharm

환인제약 · 016580

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$136.4M (₩188.2B)

Overview

Whanin Pharm makes prescription and over-the-counter medicines supplied to hospitals, clinics, and pharmacies across South Korea.

The company is listed on KOSPI, South Korea's main stock exchange. Its filing covers a broad portfolio of pharmaceutical products alongside active research and development activity, suggesting the business spans both established medicines and pipeline compounds.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$184.9M

▼ −1.7% YoY

Operating profit · FY2025

US$9.4M

▼ −39.4% YoY

Net income · FY2025

US$9.9M

▼ −41.9% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$167M(₩230.4B)	US$188.1M(₩259.6B)	US$184.9M(₩255.2B)
Operating profit	US$21.9M(₩30.2B)	US$15.6M(₩21.5B)	US$9.4M(₩13B)
Net income	US$21.6M(₩29.8B)	US$16.9M(₩23.4B)	US$9.9M(₩13.6B)

Revenue

FY2023US$167M
FY2024US$188.1M
FY2025US$184.9M

Operating profit

FY2023US$21.9M
FY2024US$15.6M
FY2025US$9.4M

Net income

FY2023US$21.6M
FY2024US$16.9M
FY2025US$9.9M

Key ratios (FY2025)

ROE

3.2%

Debt/Eq

13.8%

Op. margin

5.1%

Net margin

5.3%

Rev. YoY

▼ −1.7%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?